Searchable abstracts of presentations at key conferences in endocrinology

ea0029p852 | Endocrine tumours and neoplasia | ICEECE2012

Effect of dopamine agonists on the tumor size of prolactinomas: are suppressive doses different from those that normalize prolactin serum levels?

Sardella C. , Urbani C. , Lombardi M. , Manetti L. , Cosci C. , Brogioni S. , Marchello A. , Martino E. , Bogazzi F.

Prolactin-secreting (PRL) adenomas are about 40% of all pituitary adenomas. The most important clinical symptoms of PRL excess are gonadal and sexual dysfunction as a result of tumor expansion in patients with macroadenomas. Medical therapy of prolactinomas relies on the use of dopamine agonists which induce normalization of PRL levels and shrinkage of the tumor mass in the majority of patients. The present study evaluated whether doses of dopamine agonist inducing normalizati...

ea0029p1580 | Thyroid (non-cancer) | ICEECE2012

The role of surgery in the treatment of amiodarone-induced thyrotoxicosis (AIT)

Tomisti L. , Materazzi G. , Marchello A. , Moretti M. , De Napoli L. , Brogioni S. , Miccoli P. , Bogazzi F. , Martino E.

Introduction: AIT develops in 15–20% of patients receiving amiodarone. Patients with persistent thyrotoxicosis or those with instable cardiac function, may be candidate for thyroidectomy; however, thyrotoxicosis and underlying cardiovascular disease may increased surgical risk.Matherials and methods: We retrospectively selected 23 AIT patients treated with a total thyroidectomy, from January 2000 to December 2010 [19 men, 4 women; mean (+SD), age 61...